Denosumab (Prolia, Xgeva)

Denosumab is a monoclonal antibody against the protein RANKL (RANKL is important for the maintenance of healthy bone but when elevated (in osteoporosis and cancers that spread to bone) it causes osteoporosis). Denosumab (brand name XGEVA) is FDA-approved for the prevention of fractures in patients with solid tumors metastasized to bone, including prostate cancer.